Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antenatal screening for chromosomal abnormalities

13 Mar 2022

Abstract excerpt

Screening for chromosomal disorders, especially for trisomy 21, has undergone a number of changes in the last 50 years. Today, cell-free DNA analysis (cfDNA) is the gold standard in screening for trisomy 21. Despite the advantages that cfDNA offers in screening for common trisomies, it must be recognized that it does not address many other chromosomal disorders and any of the structural fetal anomalies. In the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Anomalies and Fetal Surgery
Share to Genomic variations and chromosomal abnormalities
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35279726
DOI: 10.1007/s00404-022-06477-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antenatal screening for chromosomal abnormalitiesPMID 35279726Read ↗

ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practiceSemantic proximity Read ↗

Current controversies in prenatal diagnosis 2: Cell‐free DNA prenatal screening should be used to identify all chromosome abnormalitiesSemantic proximity Read ↗

Clinical Perspective of Cell-Free DNA Testing for Fetal AneuploidiesSemantic proximity Read ↗

Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening?Semantic proximity Read ↗

Noninvasive Prenatal TestingSemantic proximity Read ↗

Cell-Free DNA Testing for Fetal Chromosomal Anomalies in clinical practice: Austrian-German-Swiss Recommendations for non-invasive prenatal tests (NIPT)Semantic proximity Read ↗

Cell‐free <scp>DNA</scp> testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10–14 weeks and meta‐analysisSemantic proximity Read ↗

Quality Requirements for the early Fetal Ultrasound Assessment at 11–13+6 Weeks of Gestation (DEGUM Levels II and III)Semantic proximity Read ↗

Initial experience with non-invasive prenatal testing of cell-free DNA for major chromosomal anomalies in a clinical settingSemantic proximity Read ↗

Combined First Trimester Screening and Cell-Free Fetal DNA – “Next Generation Screening”Semantic proximity Read ↗

Guideline No. 456: Prenatal Screening for Fetal Chromosomal AnomaliesSemantic proximity Read ↗

Cell-free DNA Analysis for Noninvasive Examination of TrisomySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.